Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jan;2(1):86-98.
doi: 10.1602/neurorx.2.1.86.

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

Affiliations
Review

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

Wolfgang Löscher et al. NeuroRx. 2005 Jan.

Abstract

The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances. BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS. The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB. In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function. Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain. However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases. Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication. Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Localization of selected drug efflux proteins on brain capillary endothelial cells that form the blood-brain barrier. Only transporters that are localized on the apical (luminal) side of the brain capillary endothelium would be in a position to restrict brain uptake of xenobiotics. Note that the exact localization in endothelial cells has not been demonstrated as yet for all transporters shown in the figure, but for some of the transporters the localization (apical vs basolateral) was derived from studies on polarized epithelial cell lines.

References

    1. Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 61: 682–699, 2004. - PMC - PubMed
    1. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J 376: 313–338, 2003. - PMC - PubMed
    1. Silverman JA. Multidrug-resistance transporters. Pharm Biotechnol 12: 353–386, 1999. - PubMed
    1. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69–74, 2000. - PubMed
    1. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931–959, 2001. - PMC - PubMed

Publication types

Substances